Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients
The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
Abstract
New fecal microbiota for cancer patients: The composition of the gut microbiome influences the response of cancer patients to immunotherapies. Baruch et al. and Davar et al. report first-in-human clinical trials to test whether fecal microbiota transplantation (FMT) can affect how metastatic melanoma patients respond to anti–PD-1 immunotherapy (see the Perspective by Woelk and Snyder). Both studies observed evidence of clinical benefit in a subset of treated patients. This included increased abundance of taxa previously shown to be associated with response to anti–PD-1, increased CD8 + T cell activation, and decreased frequency of interleukin-8–expressing myeloid cells, which are involved in immunosuppression. These studies provide proof-of-concept evidence for the ability of FMT to affect immunotherapy response in cancer patients. Science , this issue p. 602 , p. 595 ; see also p. 573
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The gut microbiome has an important role to play in ICI response7,8, as we also confirmed here”
From Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma (2022) · cites this paper as [7]
In the citing paper
“Although we confirmed that the microbiome holds the potential to support the clinical practice for the treatment of patients with melanoma, as shown via fecal microbiota transplantation pilots7,8”
From Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma (2022) · cites this paper as [7]
In the citing paper
“Furthermore, two clinical trials unexpectedly found that FMT from ICI responders combined with anti-PD-1 therapy overcame resistance to PD-1 blockade in melanoma patients in 2021 [14, 15].”
From Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies (2022) · doi:10.1186/s13045-022-01273-9 · cites this paper as [15]
In the citing paper
“Currently, several lines of evidence from preclinical to clinical research have gradually established that the gut microbiota can modulate antitumor immunity and affect the efficacy of cancer immunotherapies, especially immune checkpoint inhibitors (ICIs).”
From Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies (2022) · doi:10.1186/s13045-022-01273-9 · cites this paper as [15]
In the citing paper
“The results showed that three of the ten patients showed tumor volume decline, including two partial responses (PR) and one complete response (CR) [15].”
From Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies (2022) · doi:10.1186/s13045-022-01273-9 · cites this paper as [15]
25 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
Wickham, H. (2016) · Use R! · doi:10.1007/978-3-319-24277-4 · Cited by 33,115
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2
Bolyen, E., Rideout, J. R., Dillon, M. R., Bokulich, N. A., Abnet, C. C., Al-Ghalith, G. A., Alexander, H., Alm, E. J., Arumugam, M., Asnicar, F., et al. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0209-9 · Cited by 23,742
ggplot2: Elegant Graphics for Data Analysis
Wickham, H. (2009) · doi:10.1007/978-0-387-98141-3 · Cited by 14,447
Greengenes, a Chimera-Checked 16S rRNA Gene Database and Workbench Compatible with ARB
DeSantis, T. Z., Hugenholtz, P., Larsen, N., Rojas, M., Brodie, E. L., Keller, K., Huber, T., Dalevi, D., Hu, P., & Andersen, G. L. (2006) · Applied and Environmental Microbiology · doi:10.1128/aem.03006-05 · Cited by 10,891
UniFrac: a New Phylogenetic Method for Comparing Microbial Communities
Lozupone, C., & Knight, R. (2005) · Applied and Environmental Microbiology · doi:10.1128/aem.71.12.8228-8235.2005 · Cited by 8,227
Conservation evaluation and phylogenetic diversity
Faith, D. P. (1992) · Biological Conservation · doi:10.1016/0006-3207(92)91201-3 · Cited by 5,693
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588
Self-citation
Cited by
Items 901–1,000 of 1,002
The Prospect of Harnessing the Microbiome to Improve Immunotherapeutic Response in Pancreatic Cancer
Rogers, S. C., Charles, A. M., & Thomas, R. M. (2023) · Cancers · doi:10.3390/cancers15245708 · Cited by 11
Liu, B., Liu, Z., Jiang, T., Gu, X., Yin, X., Cai, Z., Zou, X., Dai, L., & Zhang, B. (2024) · European journal of medical research · doi:10.1186/s40001-024-01741-7 · Cited by 13
Gastric Cancer, Immunotherapy, and Nutrition: The Role of Microbiota
Raoul, P. C., Gaetano, V. D., Sciaraffia, G., Ormea, G., Cintoni, M., Pozzo, C., Strippoli, A., Gasbarrini, A., Mele, M. C., & Rinninella, E. (2024) · Pathogens · doi:10.3390/pathogens13050357 · Cited by 11
Mining the Gut Microbiota for Microbial-Based Therapeutic Strategies in Cancer Immunotherapy
Li, B., Gong, T., Hao, Y., Zhou, X., & Cheng, L. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.721249 · Cited by 9
Adenosine-Deaminase-Acting-on-RNA-1 Facilitates T-cell Migration toward Human Melanoma Cells
Margolis, N., Moalem, H., Meirson, T., Galore-Haskel, G., Markovits, E., Baruch, E. N., Vizel, B., Yeffet, A., Kanterman-Rifman, J., Debby, A., et al. (2022) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-21-0643 · Cited by 10
Self-citationSakai, S. A., Aoshima, M., Sawada, K., Horasawa, S., Yoshikawa, A., Fujisawa, T., Kadowaki, S., Denda, T., Matsuhashi, N., Yasui, H., et al. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.925444 · Cited by 13
Kurzhals, J. K., Klee, G., Hagelstein, V., Zillikens, D., Terheyden, P. A. M., & Langan, E. A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810723 · Cited by 9
Vihinen, H., Jokinen, A., Laajala, T. D., Wahid, N., Peltola, L., Kettunen, T., Rönkä, A., Tiainen, L., Skyttä, T., Kohtamäki, L. M., et al. (2023) · Clinical Lung Cancer · doi:10.1016/j.cllc.2023.01.004 · Cited by 11
Harnessing Microbiota to Improve Immunotherapy for Gastrointestinal Cancers
Goc, J., & Sonnenberg, G. F. (2022) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-22-0164 · Cited by 8
Intestinal Microbiota: The Driving Force behind Advances in Cancer Immunotherapy
Dai, Z., Fu, J., Peng, X., Tang, D., & Song, J. (2022) · Cancers · doi:10.3390/cancers14194796 · Cited by 9
Naddaf, R., Carasso, S., Levi, G. R., Hasnis, E., Qarawani, A., Maza, I., Gefen, T., Half, E., & Geva‐Zatorsky, N. (2023) · Scientific Reports · doi:10.1038/s41598-023-47723-3 · Cited by 10
The role of the gut microbiome in regulating the response to immune checkpoint inhibitor therapy
Dean, N. J., d’Arienzo, P. D., Ibraheim, H., Lee, K. A., Olsson-Brown, A. C., Pinato, D. J., & Powell, N. (2024) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2024.101944 · Cited by 9
Sui, Y., Zhang, T., Ou, S., Li, G., Liu, L., Lu, T., Zhang, C., Cao, Y., Bai, R., Zhou, H., et al. (2025) · npj Biofilms and Microbiomes · doi:10.1038/s41522-025-00695-w · Cited by 8
Unraveling the Role of the Microbiota in Cancer Immunotherapy: A New Frontier
Wang, S., Li, S., Zhang, M., Liu, R., Ye, X., Mao, S., Yu, J., Xie, X., & Tan, W. (2025) · Research · doi:10.34133/research.0744 · Cited by 13
Roznovan, C. N., Marutescu, L. G., & Pîrcălăbioru, G. G. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26136177 · Cited by 13
Bryson, S., Sisson, Z., Nelson, B., Grove, J., Reister, E., Liachko, I., Auch, B., Graiziger, C. T., & Khoruts, A. (2025) · Gut Microbes · doi:10.1080/19490976.2025.2559019 · Cited by 9
Jia, R. F., Xiao, C., Zhang, Y., Hu, L.-Y., Jun-jun, Y., Zuo, R., Hu, Y., Xie, Y.-H., Ma, X., Li, Q., et al. (2025) · Drug Resistance Updates · doi:10.1016/j.drup.2025.101311 · Cited by 11
Makkar, S. K., & Bishnupuri, K. S. (2025) · Frontiers in Physiology · doi:10.3389/fphys.2025.1676796 · Cited by 11
Lu, L., Johnson, C. H., Khan, S. A., & Irwin, M. (2026) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2026.01.004 · Cited by 11
Hu, S., Luo, C., Wan, S., Zhang, S., Li, N., Liu, G., & Zhao, L.-Y. (2026) · BMC Cancer · doi:10.1186/s12885-026-15655-6 · Cited by 10
Engineering microbial metabolites to modulate tumor immunity and advance cancer immunotherapy
Chigozie, V. U., & Esimone, C. O. (2026) · Discover Immunity. · doi:10.1007/s44368-026-00019-w · Cited by 11
Microbe-driven immune suppression in colorectal cancer: the Fusobacterium nucleatum playbook
Wuyi, W., & Tao, P. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1795703 · Cited by 14
Immunodiagnosis — the promise of personalized immunotherapy
Wang, R., Xiong, K., Wang, Z., Wu, D., Hu, B., Ruan, J., Sun, C., Ma, D., Li, L., & Liao, S. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1216901 · Cited by 9
Gonçalves, M., Lopes, C. C. C., & Silva, P. (2024) · Tissue and Cell · doi:10.1016/j.tice.2024.102306 · Cited by 13
Melanoma—Modern Treatment for Metastatic Melanoma
Dimitrova, M., & Weber, J. S. (2024) · The Cancer Journal · doi:10.1097/ppo.0000000000000707 · Cited by 11
Immunotherapy efficacy and toxicity: Reviewing the evidence behind patient implementable strategies
Verhaert, M., & Aspeslagh, S. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.114235 · Cited by 11
The influence of microbiota on the efficacy and toxicity of immunotherapy in cancer treatment
Mahmoudian, F., Gheshlagh, S. R., Hemati, M., Farhadi, S., & Eslami, M. (2024) · Molecular Biology Reports · doi:10.1007/s11033-024-10188-2 · Cited by 15
Spakowicz, D. J., Bibi, A., Muniak, M., Williams, N. F., Hoyd, R., & Presley, C. J. (2021) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2021.02.001 · Cited by 8
Feng, Z., & Vuky, J. (2021) · ONCOLOGY · doi:10.46883/onc.2021.3507.0410 · Cited by 8
Low Carbohydrate Diets in Cancer Therapeutics: Current Evidence
Haskins, C. P., Cohen, J., Kotecha, R. R., & Kaiser, A. (2021) · Frontiers in Nutrition · doi:10.3389/fnut.2021.662952 · Cited by 9
Innovation in Gastroenterology—Can We Do Better?
Klang, E., Soffer, S., Tsur, A., Shachar, E., & Lahat, A. (2022) · Biomimetics · doi:10.3390/biomimetics7010033 · Cited by 9
Self-citationBibliometric and visual analysis of fecal microbiota transplantation research from 2012 to 2021
Zhang, F., Yang, P., Chen, Y., Wang, R., Liu, B., Wang, J., Yuan, M., & Zhang, L. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.1057492 · Cited by 9
Holistic immunomodulation for small cell lung cancer
Leung, E. L., Fan, X., Huang, J., Huang, C., Lin, H., & Cao, Y. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.11.012 · Cited by 8
Fecal Microbiota Transplantation Research over the Past Decade: Current Status and Trends
Hao, S., Yang, S., Zhang, N., & Cheng, H.-J. (2023) · Canadian Journal of Infectious Diseases and Medical Microbiology · doi:10.1155/2023/6981721 · Cited by 8
Targeting microbiome, drug metabolism, and drug delivery in oncology
Sumiyoshi, A., Fujii, H., & Okuma, Y. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114902 · Cited by 9
Cao, Y., Zhang, L., Xiong, F., Guo, X., Kan, X., Song, S., Liang, B., Liang, B., Li, Y., & Zheng, C. (2023) · Future Microbiology · doi:10.2217/fmb-2022-0234 · Cited by 9
Angrish, M. D., & Pezo, R. C. (2021) · Advances in Cancer Biology - Metastasis · doi:10.1016/j.adcanc.2021.100020 · Cited by 8
Zhou, L., Yang, Y., Si, L., Chi, Z., Sheng, X., Lian, B., Wang, X., Tang, B., Mao, L., Yan, X., et al. (2022) · Melanoma Research · doi:10.1097/cmr.0000000000000809 · Cited by 8
Antibiotic Therapy: The Cornerstone of Iatrogenic Resistance to Immune Checkpoint Inhibitors
Pinato, D. J., & Cortellini, A. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.00049 · Cited by 8
Microbiome‐driven anticancer therapy: A step forward from natural products
Guan, Y., Wu, D., Wang, H., & Liu, N. (2024) · mLife · doi:10.1002/mlf2.12118 · Cited by 7
The skin microbiome in dermatologic disease
MacGibeny, M. A., Adjei, S., Pyle, H. J., Bunick, C. G., Ghannoum, M. A., Grada, A. A., Harris-Tryon, T. A., Tyring, S. K., & Kong, H. H. (2024) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2024.07.1499 · Cited by 9
Lu, D., Ji, L., Liu, F., Liu, H., Sun, Z., Yan, J., & Hua, W. (2024) · Current Drug Delivery · doi:10.2174/0115672018304338241003095955 · Cited by 7
Yang, W., Zhang, W., Huang, X., Geng, S., Zhai, Y., Jiang, Y., Tian, T., Gao, Y., He, J., Huang, T., et al. (2025) · Engineering · doi:10.1016/j.eng.2024.10.023 · Cited by 7
Wong, M. K., Boukhaled, G. M., Armstrong, E., Liu, R., Heirali, A., Yee, N., Tsang, J., Spiliopoulou, P., Schneeberger, P. H. H., Wang, B. X., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010681 · Cited by 8
Gut microbiota as a predictive tool for outcomes in IgA nephropathy
Dong, Y., Yan, G., Zhang, Y., Zhou, Y., & Shang, J. (2025) · Renal Failure · doi:10.1080/0886022x.2025.2514184 · Cited by 7
Emerging strategies in colorectal cancer immunotherapy: enhancing efficacy and survival
Zhang, Y., Guan, H., Feng, X., Liu, M., Shao, J., Liu, M., He, J., Jin, Y., Zhu, J., & Zheng, C. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1616414 · Cited by 13
Microbiota: a dawn for cancer metastasis therapy
Xia, S., Jia, D., & Wang, L. (2025) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2025.09.008 · Cited by 9
Wang, F., Fan, J., Pan, W., Liu, M., Wang, J., Wei, X., Xian, Y., Chen, S., Cui, C., Chen, Y., et al. (2025) · Bioactive Materials · doi:10.1016/j.bioactmat.2025.10.012 · Cited by 14
The Microbiome and Genitourinary Cancers: A New Frontier
Winslow, T. B., Gupta, S., Vaddaraju, V., Guercio, B. J., & Sahasrabudhe, D. M. (2025) · Cancers · doi:10.3390/cancers17223606 · Cited by 7
Lucia, S. S. D., Nista, E. C., Candelli, M., Archilei, S., Deutschbein, F., Capuano, E., Gasbarrini, A., Franceschi, F., & Pignataro, G. (2025) · Cancers · doi:10.3390/cancers17223618 · Cited by 7
Quan, L., Rong, H., Yue, J., Xu, J., Zheng, Y., & Yuan, P. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-07355-9 · Cited by 8
Li, Q., & Liu, Y. (2025) · Frontiers in Microbiology · doi:10.3389/fmicb.2025.1701101 · Cited by 7
Microbiota and cancer immunotherapy: Mechanisms, clinical implications, and precision therapeutics
Wei, D., Sun, Y., Han, J., & Liu, J. (2025) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2025.12.002 · Cited by 9
Yoshinami, Y., Yamaguchi, S., Shoji, H., Okita, N. T., Takamaru, H., Hirose, T., Hirano, H., Takashima, A., Imazeki, H., Yamamoto, S., et al. (2025) · Future Oncology · doi:10.1080/14796694.2025.2599371 · Cited by 8
Cao, P., Li, Q., Li, Y., Guo, H., Wei, C., Xu, R., Ouyang, C., Chen, W., Wang, L., & Wang, Z. (2025) · Nature Communications · doi:10.1038/s41467-025-67437-6 · Cited by 12
Microbiota and tumor epigenetics: deep interconnections and emerging therapeutic perspectives
Duan, L., Hu, D., Zhang, H., & Liao, Y. (2026) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2025.2602551 · Cited by 9
Yang, J., Dai, Y., & Li, J. (2026) · Oncology Reviews · doi:10.3389/or.2025.1687901 · Cited by 9
Zhou, H., Sun, R., Nie, X., Xia, L., Dong, H., Liu, Y., Hou, S., Dong, W., Zhu, X., Yao, Y., et al. (2026) · Nature Microbiology · doi:10.1038/s41564-026-02279-6 · Cited by 13
Microbiota-derived metabolites as modulators of cancer immunotherapy response
Toner-Bartelds, C., Mimpen, I. L., Parra-Martinez, M., Burgering, B. M. T., & Voest, E. E. (2026) · Nature Communications · doi:10.1038/s41467-026-72178-1 · Cited by 10
Understanding the human gut microbiome: from composition to disease association
Alali, M. A., & Shori, A. B. (2026) · Frontiers in Microbiomes · doi:10.3389/frmbi.2026.1717288 · Cited by 14
The Urogenital System’s Role in Diseases: A Synopsis
Zerdan, M. B., Moukarzel, R., Naji, N. S., Bilen, Y., & Nagarajan, A. (2022) · Cancers · doi:10.3390/cancers14143328 · Cited by 8
Research highlights in cancer immunotherapy from basic discovery to clinical trial
Wang, C. (2022) · Holistic Integrative Oncology · doi:10.1007/s44178-022-00012-x · Cited by 8
Drobner, J. C., Lichtbroun, B. J., Singer, E. A., & Ghodoussipour, S. B. (2023) · Technology in Cancer Research & Treatment · doi:10.1177/15330338231164196 · Cited by 8
Crosstalk between Gut Microbiota and Hepatocellular Carcinoma
Xie, C., & Pocha, C. (2023) · Gastrointestinal Disorders · doi:10.3390/gidisord5020013 · Cited by 7
Potential role of gut microbes in the efficacy and toxicity of immune checkpoints inhibitors
Ma, J., Wei, Q., Cheng, X. M., Zhang, J., Zhang, Z., & Su, J. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1170591 · Cited by 9
The Value of Microbes in Cancer Neoantigen Immunotherapy
Tian, J., & Ma, J. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15082138 · Cited by 8
Mécanismes de résistance aux traitements des cancers
Fessart, D., & Robert, J. (2023) · Bulletin du Cancer · doi:10.1016/j.bulcan.2023.07.001 · Cited by 12
The impact of Parkinson’s disease-associated gut microbiota on the transcriptome in Drosophila
Liu, X., Yang, M., Liu, R., Zhou, F., Zhu, H., & Wang, X. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.00176-23 · Cited by 9
Exercise and the gut microbiome: implications for supportive care in cancer
Hart, N. H., Wallen, M. P., Farley, M. J., Haywood, D., Boytar, A. N., Secombe, K. R., Joseph, R., Chan, R. J., Kenkhuis, M., Buffart, L. M., et al. (2023) · Supportive Care in Cancer · doi:10.1007/s00520-023-08183-7 · Cited by 15
Microbes and vitamin D aid immunotherapy
Franco, F., & McCoy, K. D. (2024) · Science · doi:10.1126/science.adp1309 · Cited by 7
Oliva, M., Heirali, A., Watson, G. A., Rooney, A. M., Cochrane, K., Jennings, S., Taylor, R., Xu, M., Hosni, A., Hope, A. J., et al. (2024) · British Journal of Cancer · doi:10.1038/s41416-024-02701-y · Cited by 8
Hazra, R., Chattopadhyay, S., Mallick, A., Gayen, S., & Roy, S. (2024) · Medical Oncology · doi:10.1007/s12032-024-02416-3 · Cited by 8
Ding, R., Lu, J., Huang, X., Deng, M., Wei, H., Jiang, G., Zhu, H., & Yuan, H. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113100 · Cited by 8
Could intratumoural microbiota be key to unlocking treatment responses in hepatocellular carcinoma?
Yu, K. L., & Shen, S. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.115195 · Cited by 8
Rafie, E., Zugman, M., Pal, S. K., Routy, B., & Elkrief, A. (2024) · European Urology Focus · doi:10.1016/j.euf.2024.12.009 · Cited by 7
Das, M., Kiruthiga, C., Shafreen, R. B., Nachammai, K. T., Selvaraj, C., & Kulanthaivel, L. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177436 · Cited by 8
The Oral Microbiome and Cancer
Deng, J., Sun, C., Xu, G., Wang, B., Tzortzopoulou, E., Deng, D., & Giovannetti, E. (2025) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-79146-8_10 · Cited by 11
Fecal microbiota transplantation: can it circumvent resistance to PD-1 blockade in melanoma?
Derosa, L., & Zitvogel, L. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00585-5 · Cited by 6
Microbiome-based therapeutics: Opportunity and challenges
Pant, A., & Das, B. (2022) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2022.07.006 · Cited by 10
The Crosstalk between Microbiome and Immunotherapeutics: Myth or Reality
Tojjari, A., Abushukair, H. M., & Saeed, A. (2022) · Cancers · doi:10.3390/cancers14194641 · Cited by 9
The Interplay between Anti-Angiogenics and Immunotherapy in Colorectal Cancer
Maiorano, B. A., Parisi, A., Maiello, E., & Ciardiello, D. (2022) · Life · doi:10.3390/life12101552 · Cited by 9
Hilakivi-Clarke, L. A., Verma, V., McDermott, M., Koak, P., & Andrade, F. D. O. (2022) · Frontiers in Microbiomes · doi:10.3389/frmbi.2022.1049688 · Cited by 7
Tumor resident microbiota and response to therapies: An insight on tissue bacterial microbiota
Pirini, F., Cortesi, M., Tumedei, M. M., Zanoni, M., Ravaioli, S., & Bravaccini, S. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.1048360 · Cited by 7
Bhatt, A., Haslam, A., & Prasad, V. K. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-04656-8 · Cited by 8
Role of the Microbiome in Immunotherapy of Melanoma
Jiminez, V. S., & Yusuf, N. (2023) · The Cancer Journal · doi:10.1097/ppo.0000000000000648 · Cited by 8
Gastrointestinal injury induced by immunomodulators: A review article
Zhang, P., Mao, R., Zhang, C., Qiu, Y., & Chen, M. (2023) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848231158549 · Cited by 10
Fecal transplantation in patient with metastatic melanoma refractory to immunotherapy: A case report
del Giglio, A., & Atuí, F. C. (2023) · World Journal of Clinical Cases · doi:10.12998/wjcc.v11.i24.5830 · Cited by 7
Factors of faecal microbiota transplantation applied to cancer management
Liu, Y.-H., Chen, J., Chen, X., & Liu, H. (2024) · Journal of drug targeting · doi:10.1080/1061186x.2023.2299724 · Cited by 6
Clinical Applications of the Gut Microbiome in Genitourinary Cancers
Nguyen, C. B., & Vaishampayan, U. N. (2024) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_100041 · Cited by 8
Faecal transplants can treat some cancers — but probably won’t ever be widely used
Drew, L. (2024) · Nature · doi:10.1038/d41586-024-02212-z · Cited by 6
Effects of antibiotics on immunotherapy in patients with metastatic nonsmall cell lung cancer
Hu, T., Li, L., Cui, J., Song, X., Zhu, H., Hou, Z. W., & Yuan, S. (2024) · European Journal of Cancer Prevention · doi:10.1097/cej.0000000000000912 · Cited by 7
Hadjigeorgiou, A. G., Harkos, C., Mishra, A. K., Morad, G., Johnson, S. B., Ajami, N. J., Wargo, J. A., Munn, L. L., Stylianopoulos, T., & Jain, R. K. (2025) · Cancer Research · doi:10.1158/0008-5472.can-24-2232 · Cited by 17
Self-citationWang, R., Zhong, D., Jin, K., Tong, A., Li, L., Zheng, Y., Cui, J., Liu, X., Wang, Z., & Zhou, M. (2025) · Cell Biomaterials · doi:10.1016/j.celbio.2025.100182 · Cited by 8
Microbiome unlocks cancer immunotherapeutic potential: State of the art and future
Luo, H.-Y., Cao, L., Zhou, K., Xiao, Y., Li, Z., Liu, B., & Bu, L. (2025) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2025.08.001 · Cited by 6
Yang, J., Dong, Y., Chen, Y., Liang, H., Rong, S., Liu, Z., & Lang, Q. (2025) · Oncology Letters · doi:10.3892/ol.2025.15273 · Cited by 10
Microbial Metabolic Pathways Guide Response to Immune Checkpoint Blockade Therapy
Mimpen, I. L., Battaglia, T., Parra-Martinez, M., Toner-Bartelds, C., Zeverijn, L. J., Geurts, B. S., Verkerk, K., Hoes, L. R., van Renterghem, A. W. J., Noë, M., et al. (2025) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-1669 · Cited by 11
Research progress on gut microbiota in colorectal cancer immunotherapy
Li, J., Yue, Y., Pan, J., & Liang, F. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189476 · Cited by 7
Unveiling the interplay between microbiota and PD1/PD-L1 axis in tumor immunity and immunotherapy
Lu, Q., Wu, J., Yu, X., Qian, J., & Song, Z. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1690374 · Cited by 6
Ascari, S., Chen, R., Sinno, A. D., Stefanini, B., Cescon, M., Serenari, M., Mosconi, C., & Tovoli, F. (2026) · World Journal of Gastroenterology · doi:10.3748/wjg.v32.i3.111528 · Cited by 6
Lou, S., Li, W., Wang, G., Qian, H., & Zhou, J. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105217 · Cited by 9
Metadata
- Authors
- Baruch, E. N., Youngster, I., Ben-Betzalel, G., Ortenberg, R., Lahat, A., Katz, L., Adler, K., Dick-Necula, D., Raskin, S., Bloch, N., Rotin, D., Anafi, L., Avivi, C., Melnichenko, J., Steinberg-Silman, Y., Mamtani, R., Harati, H., Asher, N., Shapira-Frommer, R., Brosh-Nissimov, T., Eshet, Y., Ben-Simon, S., Ziv, O., Khan, M. A. W., Amit, M., Ajami, N. J., Barshack, I., Schachter, J., Wargo, J. A., Koren, O., Markel, G., & Boursi, B.
- Affiliations
- Tel Aviv University (IL)
- The Ella Lemelbaum Institute for Immuno-Oncology, Sheba Medical Center, Tel-HaShomer, Israel.
- Sheba Medical Center (IL)
- Hadassah Medical Center (IL)
- Bar-Ilan University (IL)
- Institute of Pathology, Sheba Medical Center, Tel-HaShomer, Israel.
- University of Pennsylvania (US)
- Infectious Diseases Unit, Assuta Ashdod University Hospital, Ashdod, Israel.
- Azrieli Faculty of Medicine, Bar Ilan University, Safed, Israel.
- The University of Texas MD Anderson Cancer Center (US)
- Corresponding author
- Baruch, Erez N.
- Markel, Gal
- Boursi, Ben
- ORCID
- Baruch, Erez N.
- Youngster, Ilan
- Ortenberg, Rona
- Lahat, Adi
- Katz, Lior
- Adler, Katerina
- Raskin, Stephen
- Bloch, Naamah
- Rotin, Daniil
- Anafi, Liat
- Avivi, Camila
- Melnichenko, Jenny
- Steinberg-Silman, Yael
- Mamtani, Ronac
- Harati, Hagit
- Asher, Nethanel
- Shapira-Frommer, Ronnie
- Eshet, Yael
- Khan, Md Abdul Wadud
- Amit, Moran
- Ajami, Nadim J.
- Barshack, Iris
- Schachter, Jacob
- Wargo, Jennifer A.
- Koren, Omry
- Markel, Gal
- Boursi, Ben
- Venue
- Science
- Published
- 2021-02-05
- Volume
- 371
- Issue
- 6529
- Pages
- 602-609
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W3111836013
- Semantic Scholar
- 20052eb45af3e9cf18b231c32b34bc26b96d2259
- Cited by
- 1,757
- References
- 65
- Citations by year
- 2026: 360 · 2025: 328 · 2024: 272 · 2023: 326 · 2022: 299 · 2021: 171
- FWCI
- 71.95
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Keywords
- fecal microbiota transplantation, metastatic melanoma, anti-PD-1 therapy, gut microbiota, tumor microenvironment, immune cell infiltration, feasibility and safety
- MeSH terms
- Gastrointestinal Microbiome, Fecal Microbiota Transplantation, Antineoplastic Agents, Immunological, Nivolumab, Adult, Female, Humans, Immunotherapy, Intestinal Mucosa, Male, Melanoma, Middle Aged, Skin Neoplasms, Lymphocytes, Tumor-Infiltrating, CD8-Positive T-Lymphocytes, Tumor Microenvironment, Transcriptome, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.